S49076

Research use only, not for human use.

S49076 is a potent, ATP-competitive tyrosine kinase inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 of <20 nM.

S49076 is a potent, ATP-competitive tyrosine kinase inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 of <20 nM, also potently inhibits the kinase activity of mutated isoforms of MET (D1246N, Y1248D, Y1248H) and FGFR1/2; only inhibits 6% of kinases on a panel of 442 human wild-type and mutated kinases at 100 nM; inhibits the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocks MET-driven migration of lung carcinoma cells, and inhibits colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL; causes tumor growth arrest in bevacizumab-resistant tumors in cancer xenograft models.Brain Cancer Phase 2 Clinical

S 49076;S-49076

Tyrosine Kinase

TAM Receptor

AXL;FGFR2;FGFR3;Mer;Met

Cancer

Brain Cancer

1265965-22-7

438.50

C22H22N4O4S

>98% (HPLC)

DMSO: ≥ 31 mg/mL

O=C(N1CC2=CC3=C(NC(/C3=C\C4=CC(CN5CCOCC5)=CN4)=O)C=C2)SCC1=O

2,4-Thiazolidinedione, 3-[[2,3-dihydro-3-[[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene]-2-oxo-1H-indol-5-yl]methyl]-

(-20℃)

With Ice Pack

≥ 2 years